Houston Gene Therapeutics, LLC

We are raising $3-10 million to push HGT-Cardio-1 toward clinical trials.

Facebook Twitter LinkedIn

See our latest News below on our HGT-Cardio-1 treatment besting simvastatin in inhibiting atherosclerosis in the LDLR-KO HCD mouse model, and being a new standard of care in the clinic if verified by human clinical trials .

Houston Gene Therapeutics LLC, 8990 Kirby Dr Ste 220, Houston, TX  77054, website https://www.houstongenetherapeutics.com. Paul Hermonat, PhD, CEO, 501-940-7034, [email protected]
Paul Hermonat, PhD founded Houston Gene Therapeutics, June 24, 2019
Overview: Houston Gene Therapeutics LLC
8990 Kirby Dr Ste 220, Houston, TX  77054, website https://www.houstongenetherapeutics.com.  Paul Hermonat, PhD, CEO, 501-940-7034, [email protected],  

A company Logo

Houston Gene Therapeutics, LLC:  We are raising $$$ to push HGT's newly allowed anti-vascular disease AAV-based gene therapy treatment, HGT-Cardio-1, toward the clinic by carrying out toxicology, IND, Phase I, II, and III testing.  Also, we will continue to further develop treatments for aging, dyslipidemia, and cancer.  See: NEWS RELEASE  https://www.marketwatch.com/press-release/first-patent-issued-to-leading-biotechnology-company-houston-gene-therapeutics-2021-07-29 
Latest News on HGT-Cardio-1, our initial "big hitter" product, which  against atherosclerosis.    HGT-Cardio-1 is very promising as a new "standard of care" for atherosclerosis.
HGT-Cardio-1 is now protected by two US Patents: 11,091,524 and 11,274,134 with others submitted.  It has been highly  effective in our animal model LDLR-KO mice on high cholesterol diet (HCD).   However, how is this better than statin treatments, present "standard of Care (SOC)".   Below see our most central data on comparing simvastatin and HGT-Cardio-1 by doing a 2 Study Comparison.  We concentrated the most critical data as a figure just below.  In addition statins must be taken daily, while gene therapy lasts 10 years.

The left figure shows systolic blood velocity at the arch of the aorta in the mice. The higher the blood velocity the more atherosclerosis there is. This is from patent 11,091,524. The inhibition from statin treatment is from the Wang Xi-Xin paper. Notice that the inhibition of atherosclerosis, in percent inhibition, in the LDLR-KO HCD mice is much higher when treated by HGT-Cardio-1 compared to simvastatin treatment which studies "en face" plaque levels. Additionally the amount of simvastatin used in the Wang Xi-Xin study was extremely high, the equivalent of 20 grams for a human man. A similar effect can be seen in the Figure on the right which measures the wall thickness in the arch in the HGT-cardio-1 study compare to simvastatin . These data suggest rather strongly that HGT-Cardio-1 is more effective than simvastatin for treating atherosclerosis in the LDLR-KO on HCD mouse model, which is the mouse model which best mimics the human disease situation. Of course these results needs to be further studied in human clinical trials. We also have a second 2-study comparison which shows HGT-Cardio-1 besting Pravastatin.

Investment request: Houston Gene Therapeutics (HGT), LLC, is an AAV-based gene therapy company which intends to treat the major diseases of our time (inflammation, cancer aging) using the new AAV gene therapy approach.  Presently, based at 8890 Kirby Dr Ste 220, Houston, TX 77054, HGT has two issued (USP 11,091,524, USP 11,274,134) on HGT-Cardio-1) and one pending US PAT on the treatment of vascular (eg. atherosclerosis-inflammatory) disease, with two more in preparation.  For funding, we are trying to raise $2M for HGT-Cardio-1 toxicology studies in large animal models (Duroc piglets and Cynomolgus monkeys) and an additional $5M+ towards IND & Phase I, II, III Clin Trials.  We would also like to receive $3M for further pre-clinical R&D for our hypertension, dyslipidemia and aging gene therapy products.  Overall, that is about a $10M request to give HGT a good start in treatment development.  Our costs are based on personal estimations and may change due to altering goals, markets, FDA compliance, reagent costs, and other changes.  
In summary, we are requesting $7M for the further development of our first anti-cardiovascular disease (atherosclerosis) gene therapy treatment; HGT-Cardio-1.  We are requesting an additional $3M for additional gene treatments development for other important diseases (Hypertension, Dyslipidemia, Aging).  At the same time, we would like to establish a brick and mortar laboratory facility to carry out experiments in-house, and have a consolidated headquarters, office space. 
To give full disclosure of the situation, investing in gene therapy/biotech is not designed for a rapid money “flip” for profit, this being due to the several years development of products to the market place, plus getting patents awarded. However, by developing a portfolio of intellectual property (eg. 17/078,163 on HGT-Cardio-1) and bringing gene therapy products to the clinical marketplace there is an outstanding chance to make large profit in the longer term.  It must be stated that as of the middle of 2021 gene therapy treatments cost roughly $1 million per patient.  Additionally, products beyond what is listed here are envisioned.
Company description:
I’m Dr. Paul Hermonat, PhD, ([email protected]) and I’ve founded Houston Gene Therapeutics, LLC (https://www.houstongenetherapeutics.com) in 2019 to carry out HGT’s vision and goals.  At HGT our goals are to create and deliver AAV-based gene therapies (AAV-GT) to treat the major diseases of our time (cardiovascular inflammation [atherosclerosis], cancer, and aging).  (https://www.houstongenetherapeutics.com/blog/allowance-of-first-patent) and another pending application for the treatment of AAV-cardiovascular disease.  Our long-term goal is to deliver safe, effective, long lasting treatments using AAV-GT/human genes as drugs.  One of our largely unique features is the use of custom transcriptional promoters which will be responsive to pathology-development within the local of the transduced cell, which will target the expression of the therapeutic gene to the site needed, thereby reducing adverse reactions. 
            We plan to make these treatments available through your physician, and/or through a network of hospitals and/or doctor’s offices, which will be recruited. 
            As HGT CEO, I’m former Endowed Chair in Cardiovascular Research, Tenured Professor of Internal Medicine, and Tenured Professor in OB/GYN of the University of Arkansas for Medical Science (for 25 years), having first received my PhD in Medical Microbiology/Immunology from the University of Florida (Gainesville), having done a postdoctoral fellowship at the National Institutes of Health (Bethesda, MD), and having been a faculty member at The John’s Hopkins University (Baltimore, MD).  I’m highly experienced in AAV gene therapy technology, the top gene therapy virus.  In fact, I was the first to generate an AAV virus carrying a foreign gene within it (rAAV), and to deliver that foreign gene into human and murine cells in culture.  My broad experience in using gene therapy to treat cardiovascular disease and cancer is documented by my publications on the use of the genes listed below:
Target Markets.
As mentioned earlier, our goal is to create and deliver AAV-based gene therapies to treat the major diseases of our time (cardiovascular inflammation [atherosclerosis], cancer, and aging).  The biggest advantage for AAV-based gene therapy is the possibility of higher efficacy, safety, and semi-permanent treatment (10 years).  Anyone over 55 is likely to have symptomatic plaque/cardiovascular disease. This group also has increased rates of cancer, in addition to being older/of advanced age.  US 55+ citizens are 21% of the population; that is about 71.4 million persons, and considering that half will develop significant cardiovascular symptoms at about 1.4 million per year.  Thus, at a cost of $500,000 patient, this, at would give revenue of $1.4x106x10-2x5x105 or $7x109 per year at 1% market penetrance or $3.5x1011 yearly revenue at 50% market penetrance.
            Moreover, everyone, as they age goes through this stage.  While this is a huge market size in the US, considering the total world population this is about 1.26 billion persons.
According to Google Analytics the following are HGT's closest competitors:
Sparktx.com with $20M revenue and 354 employees and is doing gene therapy, 
Libellagenetherapy.com does aging gene therapy and clinical trials are outside the USA, 
Renovatherapeutics.com does cardiovascular and metabolic diseases with 6 employees with no statements about revenue I could find, so it has some overlap/similar goals to HGT, but they are very small.
Catalent.com is a giant company with 14,000 employees with $3B in revenue and provides drug delivery technologies such as next-generation cell and gene therapies. Being a giant competitor its clear that gene therapy is only a small part of their portfolio.  Catalent will go on its merry way, divided among many things.   
Libella has concentrated on aging and must do clinical trials outside the US, which is a red flag.
Sparktx.com is probably one of HGT's biggest competitors, but they have concentrated on genetic syndromes of the eye which is a very small market.  
As HGT appears to have the largest targeted markets (inflammation, cancer, aging) of the companies mentioned here, and our market goals are chosen both for revenue success and for integrating with the future of medicine and giving the biggest footprint in healthcare.
Use of Proceeds.
$$$ for HGT-Cardio-1 FDA steps: toxicology (large animal), phase I, phase II, and phase III clinical trials, then go to market. R&D new products.  
We also need to hire staff and carry out further R&D toward generating additional therapies (gene therapy vectors).  These must be tested in tissue culture, animal models, and toxicology. We can adjust to funding we receive by reducing/expanding goals. 

Ready to Ask For Funding for your company?

Post a Funding Request